I. Technical Specifications
- Molecular Formula: C_182H_291N_47O_54
- Molecular Weight: 4050.6 g/mol
- CAS Number: 1415456-99-3
- Sequence: Acylated tri-substituted amylin analog (non-selective agonist)
- Appearance: White Lyophilized Powder
- Solubility: Soluble in Bacteriostatic Water
II. Compound Overview
Cagrilintide
is a long-acting amylin analog
known in research for its potent agonism of amylin receptors (AMYR).
In laboratory models, it has demonstrated a unique capacity to induce dose-dependent weight loss and reduce caloric intake
by mimicking the physiological effects of endogenous amylin. Taurus Peptides provides this compound as a highly purified, vacuum-sealed powder in 5mg and 10mg
formats. Its structural modification (acylation) allows for a significantly extended half-life, making it a primary subject for studies requiring sustained metabolic modulation.
III. Mechanism of Action (The “Science” Section)
Current literature suggests that Cagrilintide
functions primarily by binding to and activating calcitonin receptors and receptor activity-modifying proteins (RAMPs)
, which form the amylin receptor complexes. Researchers observe that this mechanism leads to a reduction in gastric emptying rates and the inhibition of postprandial glucagon secretion.
Unlike standard GLP-1 receptor agonists, Cagrilintide demonstrates high affinity for central satiety centers in the area postrema
, making it a primary candidate for studies involving synergistic metabolic pathways.
By acting on amylin receptors, it provides an alternative route for weight regulation research, particularly when investigating the “dual-agonist” approach to managing obesity and insulin resistance.
IV. Observed Research Outcomes
- Synergistic Weight Modulation: Studies observed that when evaluated alongside GLP-1 analogs (like Semaglutide), Cagrilintide noted a statistically significant increase in weight loss compared to mono-therapy models.
- Satiety Induction: Research indicates a marked decrease in voluntary food intake in animal models, associated with prolonged hypothalamic signaling of fullness.
- Glucose Homeostasis: In-vitro and in-vivo models have demonstrated improved glycemic control through the suppression of glucagon, the hormone responsible for hepatic glucose production.
V. Storage & Handling
- Storage: Lyophilized peptides should be stored at -20^\circ C. Once reconstituted, store at 4^\circ C for up to 14 days.
- Handling: Avoid agitation/shaking of the vial after reconstitution to prevent degradation of the peptide chain. Due to the acylation and larger molecular weight of Cagrilintide, gentle swirling is essential to ensure a clear, homogeneous solution. Use only sterile, pH-neutral diluents for reconstitution.
